Drug-induced lupus: Traditional and new concepts

Augusto Vaglio, Peter C Grayson, Paride Fenaroli, Davide Gianfreda, Valeria Boccaletti, Gian Marco Ghiggeri, Gabriella Moroni

Research output: Contribution to journalReview article

Abstract

Drug-induced lupus (DIL) includes a spectrum of drug-induced reactions often characterised by a clinical phenotype similar to that of idiopathic systemic lupus eruthematosus (SLE) but usually lacking major SLE complications. Different drugs may be associated with distinct clinical and serological profiles, and early recognition is crucial. Drugs traditionally associated with DIL include procainamide, hydralazine, quinidine and others, but strong associations with newer agents, such as TNF α (TNFα) inhibitors, are increasingly recognised. The pathogenic mechanisms explaining how drugs that have heterogeneous chemical structure and function lead to autoimmunity are only partially understood. However, it is likely that traditional DIL-associated agents can boost innate immune responses, particularly neutrophil responses, with neutrophil extracellular trap (NET) formation and exposure of autoantigens. Research in the field of DIL is evolving and may provide interesting models for the study of autoimmunity.

Original languageEnglish
Pages (from-to)912-918
Number of pages7
JournalAutoimmunity Reviews
Volume17
Issue number9
DOIs
Publication statusPublished - Sep 2018

Fingerprint

Pharmaceutical Preparations
Autoimmunity
Procainamide
Hydralazine
Quinidine
Autoantigens
Innate Immunity
Neutrophils
Phenotype
Research

Keywords

  • Drug-Related Side Effects and Adverse Reactions/complications
  • Humans
  • Lupus Erythematosus, Systemic/chemically induced

Cite this

Vaglio, A., Grayson, P. C., Fenaroli, P., Gianfreda, D., Boccaletti, V., Ghiggeri, G. M., & Moroni, G. (2018). Drug-induced lupus: Traditional and new concepts. Autoimmunity Reviews, 17(9), 912-918. https://doi.org/10.1016/j.autrev.2018.03.016

Drug-induced lupus : Traditional and new concepts. / Vaglio, Augusto; Grayson, Peter C; Fenaroli, Paride; Gianfreda, Davide; Boccaletti, Valeria; Ghiggeri, Gian Marco; Moroni, Gabriella.

In: Autoimmunity Reviews, Vol. 17, No. 9, 09.2018, p. 912-918.

Research output: Contribution to journalReview article

Vaglio, A, Grayson, PC, Fenaroli, P, Gianfreda, D, Boccaletti, V, Ghiggeri, GM & Moroni, G 2018, 'Drug-induced lupus: Traditional and new concepts', Autoimmunity Reviews, vol. 17, no. 9, pp. 912-918. https://doi.org/10.1016/j.autrev.2018.03.016
Vaglio A, Grayson PC, Fenaroli P, Gianfreda D, Boccaletti V, Ghiggeri GM et al. Drug-induced lupus: Traditional and new concepts. Autoimmunity Reviews. 2018 Sep;17(9):912-918. https://doi.org/10.1016/j.autrev.2018.03.016
Vaglio, Augusto ; Grayson, Peter C ; Fenaroli, Paride ; Gianfreda, Davide ; Boccaletti, Valeria ; Ghiggeri, Gian Marco ; Moroni, Gabriella. / Drug-induced lupus : Traditional and new concepts. In: Autoimmunity Reviews. 2018 ; Vol. 17, No. 9. pp. 912-918.
@article{e343ec13c27c4512bf9446fa534e779a,
title = "Drug-induced lupus: Traditional and new concepts",
abstract = "Drug-induced lupus (DIL) includes a spectrum of drug-induced reactions often characterised by a clinical phenotype similar to that of idiopathic systemic lupus eruthematosus (SLE) but usually lacking major SLE complications. Different drugs may be associated with distinct clinical and serological profiles, and early recognition is crucial. Drugs traditionally associated with DIL include procainamide, hydralazine, quinidine and others, but strong associations with newer agents, such as TNF α (TNFα) inhibitors, are increasingly recognised. The pathogenic mechanisms explaining how drugs that have heterogeneous chemical structure and function lead to autoimmunity are only partially understood. However, it is likely that traditional DIL-associated agents can boost innate immune responses, particularly neutrophil responses, with neutrophil extracellular trap (NET) formation and exposure of autoantigens. Research in the field of DIL is evolving and may provide interesting models for the study of autoimmunity.",
keywords = "Drug-Related Side Effects and Adverse Reactions/complications, Humans, Lupus Erythematosus, Systemic/chemically induced",
author = "Augusto Vaglio and Grayson, {Peter C} and Paride Fenaroli and Davide Gianfreda and Valeria Boccaletti and Ghiggeri, {Gian Marco} and Gabriella Moroni",
note = "Copyright {\circledC} 2018 Elsevier B.V. All rights reserved.",
year = "2018",
month = "9",
doi = "10.1016/j.autrev.2018.03.016",
language = "English",
volume = "17",
pages = "912--918",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "9",

}

TY - JOUR

T1 - Drug-induced lupus

T2 - Traditional and new concepts

AU - Vaglio, Augusto

AU - Grayson, Peter C

AU - Fenaroli, Paride

AU - Gianfreda, Davide

AU - Boccaletti, Valeria

AU - Ghiggeri, Gian Marco

AU - Moroni, Gabriella

N1 - Copyright © 2018 Elsevier B.V. All rights reserved.

PY - 2018/9

Y1 - 2018/9

N2 - Drug-induced lupus (DIL) includes a spectrum of drug-induced reactions often characterised by a clinical phenotype similar to that of idiopathic systemic lupus eruthematosus (SLE) but usually lacking major SLE complications. Different drugs may be associated with distinct clinical and serological profiles, and early recognition is crucial. Drugs traditionally associated with DIL include procainamide, hydralazine, quinidine and others, but strong associations with newer agents, such as TNF α (TNFα) inhibitors, are increasingly recognised. The pathogenic mechanisms explaining how drugs that have heterogeneous chemical structure and function lead to autoimmunity are only partially understood. However, it is likely that traditional DIL-associated agents can boost innate immune responses, particularly neutrophil responses, with neutrophil extracellular trap (NET) formation and exposure of autoantigens. Research in the field of DIL is evolving and may provide interesting models for the study of autoimmunity.

AB - Drug-induced lupus (DIL) includes a spectrum of drug-induced reactions often characterised by a clinical phenotype similar to that of idiopathic systemic lupus eruthematosus (SLE) but usually lacking major SLE complications. Different drugs may be associated with distinct clinical and serological profiles, and early recognition is crucial. Drugs traditionally associated with DIL include procainamide, hydralazine, quinidine and others, but strong associations with newer agents, such as TNF α (TNFα) inhibitors, are increasingly recognised. The pathogenic mechanisms explaining how drugs that have heterogeneous chemical structure and function lead to autoimmunity are only partially understood. However, it is likely that traditional DIL-associated agents can boost innate immune responses, particularly neutrophil responses, with neutrophil extracellular trap (NET) formation and exposure of autoantigens. Research in the field of DIL is evolving and may provide interesting models for the study of autoimmunity.

KW - Drug-Related Side Effects and Adverse Reactions/complications

KW - Humans

KW - Lupus Erythematosus, Systemic/chemically induced

U2 - 10.1016/j.autrev.2018.03.016

DO - 10.1016/j.autrev.2018.03.016

M3 - Review article

C2 - 30005854

VL - 17

SP - 912

EP - 918

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 9

ER -